{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:58:28Z","timestamp":1783299508797,"version":"3.54.6"},"reference-count":30,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2002,1,4]],"date-time":"2002-01-04T00:00:00Z","timestamp":1010102400000},"content-version":"vor","delay-in-days":1344,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[1998,5]]},"abstract":"<jats:p> <jats:italic>Aims<\/jats:italic>\u2007To study the absorption kinetics of sotalol following administration of different formulations. A formulation which results in fast absorption might be useful in the episodic treatment of paroxysmal supraventricular tachycardia (SVT), atrial fibrillation (Afib) or atrial flutter (Afl).<\/jats:p><jats:p> <jats:italic>Methods<\/jats:italic>\u2007In an open randomized crossover study seven healthy male volunteers were given an intravenous infusion of 20\u2003mg sotalol, for assessing the absolute bioavailability, an oral solution containing 80\u2003mg sotalol, an oral solution containing both 80\u2003mg sotalol and 20\u2003mg cisapride and an 80\u2003mg sotalol tablet, which was taken sublingually.<\/jats:p><jats:p> <jats:italic>Results\u2007The addition of cisapride decreased the time at which maximum serum concentrations were reached (t<jats:sub>max<\/jats:sub>\u200a) from 2.79 (1.85\u20134.34) h to 1.16 (0.68\u20132.30) h (P=0.009) [95% CI: \u20102.59, \u22120.55] and increased the absorption rate constant (k<jats:sub>a<\/jats:sub>\u200a) from 0.49 (0.31\u20130.69) h<jats:sup>\u22121<\/jats:sup> to 1.26 (0.52\u20135.61) h<jats:sup>\u22121<\/jats:sup> (P=0.017). The absolute bioavailability of sotalol was reduced by cisapride from 1.00\u00b10.15 to 0.70\u00b10.26 (P=0.006), while maximum serum concentrations of both oral solutions were not significantly different. Compared with the sublingually administered tablet with a median t<jats:sub>max <\/jats:sub>of 2.12 (0.89\u20133.28) h, the sotalol\/cisapride oral solution gave a smaller t<jats:sub>max<\/jats:sub> (p=0.009) [95% CI: \u22121.64, \u22120.36]. The k<jats:sub>a<\/jats:sub> of the sotalol\/cisapride solution was significanty (P=0.010) larger than the k<jats:sub>a<\/jats:sub> of 0.56 (0.33\u20130.75) h<jats:sup>\u22121<\/jats:sup><\/jats:italic> found after sublingual administration of the tablet.<\/jats:p><jats:p> <jats:italic>Conclusions<\/jats:italic>\u2007The sotalol\/cisapride oral solution might be suitable for the episodic treatment of SVT, Afib or Afl.<\/jats:p>","DOI":"10.1046\/j.1365-2125.1998.00706.x","type":"journal-article","created":{"date-parts":[[2003,5,8]],"date-time":"2003-05-08T13:30:40Z","timestamp":1052400640000},"page":"485-490","source":"Crossref","is-referenced-by-count":8,"title":["Absorption kinetics of oral sotalol combined with cisapride and sublingual sotalol in healthy subjects"],"prefix":"10.1111","volume":"45","author":[{"family":"Deneer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Lie\u2010A\u2010Huen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Kingma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Proost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Kelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Brouwers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,1,4]]},"reference":[{"key":"e_1_2_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90184-0"},{"key":"e_1_2_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(80)80014-2"},{"key":"e_1_2_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(95)90324-0"},{"key":"e_1_2_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(91)90706-Q"},{"key":"e_1_2_4_6_2","first-page":"157","article-title":"What is meant by a \u2018controlled\u2019 ventricular rate in atrial fibrillation?","volume":"63","author":"Rawles JM","year":"1990","journal-title":"Br Med J"},{"key":"e_1_2_4_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1992.165"},{"key":"e_1_2_4_8_2","first-page":"173","article-title":"Pharmacokinetics and pharmacodynamics in young, normal and elderly hypertensive subjects: a study using sotalol as a model drug.","volume":"212","author":"Ishizaki T","year":"1979","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_4_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0773.1976.tb03162.x"},{"key":"e_1_2_4_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01296657"},{"key":"e_1_2_4_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00542167"},{"key":"e_1_2_4_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1987.tb00629.x"},{"key":"e_1_2_4_13_2","doi-asserted-by":"crossref","unstructured":"Lie\u2010A\u2010HuenLPharmacokinetics and clinical pharmacology of flecainide in episodic treatment of paroxysmal atrial fibrillation. Thesis University of Groningen The Netherlands 1991","DOI":"10.1007\/978-94-011-1816-3_8"},{"key":"e_1_2_4_14_2","first-page":"85","article-title":"Drug interactions predisposing to ventricular arrhythmias.","volume":"10","author":"World Health Organisation","year":"1996","journal-title":"WHO Drug Information"},{"key":"e_1_2_4_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/56.1.69"},{"key":"e_1_2_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-5173(89)90113-0"},{"key":"e_1_2_4_17_2","doi-asserted-by":"crossref","unstructured":"KimuraM UmemuraK IkedaY et al. Pharmacokinetics and pharmacodynamics of (\u00b1)\u2010sotalol in healthy male volunteers.Br J Clin Pharmacol1996; 42:583588","DOI":"10.1111\/j.1365-2125.1996.tb00113.x"},{"key":"e_1_2_4_18_2","first-page":"32","article-title":"Bepaling van sotalol.","volume":"7","author":"IJmker J","year":"1991","journal-title":"Ziekenhuisfarmacie"},{"key":"e_1_2_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(00)85154-3"},{"key":"e_1_2_4_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600740724"},{"key":"e_1_2_4_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600741031"},{"key":"e_1_2_4_22_2","unstructured":"ProostJHCritical evaluation of the determination of bioavailability by numerical deconvolution. Thesis University of Groningen The Netherlands1987"},{"key":"e_1_2_4_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/67.3.302"},{"key":"e_1_2_4_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00614304"},{"key":"e_1_2_4_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-198911040-00007"},{"key":"e_1_2_4_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00278493"},{"key":"e_1_2_4_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03189108"},{"key":"e_1_2_4_28_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198836060-00002"},{"key":"e_1_2_4_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00606550"},{"key":"e_1_2_4_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1980.tb00502.x"},{"key":"e_1_2_4_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00561748"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2125.1998.00706.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2125.1998.00706.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2125.1998.00706.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T03:17:34Z","timestamp":1698463054000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2125.1998.00706.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1998,5]]}},"alternative-id":["10.1046\/j.1365-2125.1998.00706.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2125.1998.00706.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,5]]}}}